Geneious Biologics annotation algorithm beats IgBLAST, MiXCR says new white paper
AUCKLAND, NZ – May 2, 2018 – A white paper released today shows an annotation algorithm developed for Geneious
Biologics, a commercial software solution for antibody screening and discovery, outperforms those of open source
sequence analysis software IgBLAST and MiXCR.
The white paper outlines why accurate antibody sequence annotation is important for companies undertaking therapeutic
antibody research. Biologic drug development involves increasingly large volumes of antibody sequence data. This
introduces core problems around accurately screening huge numbers of candidate sequences to identify the most promising,
in usefully short timescales.
In a series of comparative tests, MiXCR 2.1.9, IgBLAST and Geneious Biologics annotation algorithms were tasked with
analyzing the same dataset - National Center for Biotechnology Information (NCBI) reference database SRR5754964 (Human).
Evaluating accuracy of sequence annotation is difficult due to a lack of industry gold standard data sets, however,
compared with IgBLAST and MiXCR, Geneious Biologics’ performance in annotating CDR regions and germline genes correlates
most closely with consensus results of the three algorithms. In rare cases where Geneious Biologics disagreed with
consensus results, bioinformaticians closely reviewed the result and determined that Geneious Biologics was generally
correct while both MiXCR and IgBLAST were incorrect, indicating superior performance of Geneious Biologics over these
popular open source tools.
“Speed and accuracy is absolutely fundamental for organizations undertaking highly specific research to identify and
validate potential therapeutic antibody candidates,” said white paper author and Vice President, Geneious Biologics
Solutions, Jannick Bendtsen, PhD.
“Few existing software providers offer solutions with the power to meet speed and accuracy requirements of specialist
therapeutic antibody researchers. For that reason we invest heavily in development to ensure Geneious Biologics delivers
best-in-class technology to accelerate therapeutic antibody discovery,” Dr Bendtsen said.
About Geneious Biologics
Geneious Biologics is a next generation cloud software solution purpose-built, in collaboration with industry partners,
for commercial antibody discovery and screening. Delivered through a modern intuitive, user-friendly web interface, the
platform provides a fully managed data platform and informatics system in a secure cloud computing infrastructure. For
more information about Geneious Biologics visit www.geneiousbiologics.com